HER2-Negative and CLDN18.2-Positive Gastric
Gastric and gastroesophageal junction (GEJ) adenocarcinomas are aggressive malignancies with limited treatment options. Recent advancements have identified CLDN18.2 as a promising biomarker in patients with…